A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Additional records indicate that distinct morphological forms occur in anthropogenic habitats. A granulose form (formerly known as Xanthoria aureola) has been recorded predominantly on roofs in southeastern England.
=== Subdivisions === One recent classification recognised 297 species of clematis. Consequently, taxonomists and gardeners subdivide the genus. Several classification systems exist. Magnus Johnson divided Clematis into 19 sections, several with subsections. Christopher Grey-Wilson divided the genus into 9 subgenera (Clematis, Cheiropsis, Flammula, Archiclematis, Campanella, Atragene, Tubulosae, Pseudanemone, Viorna), several with sections and subsections within them. Several of the subdivisions are fairly consistent between these two systems; for example, all of Grey-Wilson's subgenera are used as sections by Johnson. Alternatively, John Howell defined twelve groups: the Evergreen, Alpina, Macropetala, Montana, Rockery, Early Large-Flowered, Late Large-Flowered, Herbaceous, Viticella, Texensis, Orientalis, and Late Mixed groups. Many of the most popular garden forms are cultivars belonging to the Viticella section of the subgenus Flammula as defined by Grey-Wilson. These larger-flowered cultivars are often used within garden designs to climb archways, pergolas, or wall-mounted trellises, or to grow through companion plants. These forms normally have large 12–15 cm diameter upward-facing flowers and are believed to involve crosses of C. patens, C. lanuginosa, and C. viticella. Early-season, large-flowering forms such as 'Nelly Moser' tend towards the natural flowering habit of C. patens or C. lanuginosa while later-flowering forms such as ×jackmanii are nearer in habit to C. viticella.
== Criticism == Numerous critiques have been made regarding the use of impact factors, both in terms of their statistical validity and also of their implications for how science is carried out and assessed. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on the behavior of scholars, editors and other stakeholders. Criticism of impact factors also extends to its impact on researcher behavior. While the emphasis on high-impact journals may lead to strategic publishing practices that prioritize journal prestige over the quality and relevance of research, it's important to acknowledge the "privilege paradox". Younger researchers, particularly those from under-represented regions, often lack the established reputation or networks to secure recognition outside of these metrics. This can lead to a narrow focus on publishing in top-tier journals, potentially compromising the diversity of research topics and methodologies. Further criticisms argue that emphasis on impact factor results from the negative influence of neoliberal politics on academia.
Sources: en.wikipedia.org
which is 50 times bigger than the force on the left piston. The difference between force and pressure is important: the additional pressure is exerted against the entire area of the larger piston. Since there is 50 times the area, 50 times as much force is exerted on the larger piston. Thus, the larger piston will support a 50 N load – fifty times the load on the smaller piston. Forces can be multiplied using such a device. One newton input produces 50 newtons output. By further increasing the area of the larger piston (or reducing the area of the smaller piston), forces can be multiplied, in principle, by any amount. Pascal's principle underlies the operation of the hydraulic press. The hydraulic press does not violate energy conservation, because a decrease in distance moved compensates for the increase in force. When the small piston is moved downward 100 centimeters, the large piston will be raised only one-fiftieth of this, or 2 centimeters. The input force multiplied by the distance moved by the smaller piston is equal to the output force multiplied by the distance moved by the larger piston; this is one more example of a simple machine operating on the same principle as a mechanical lever. A typical application of Pascal's principle for gases and liquids is the automobile lift seen in many service stations (the hydraulic jack). Increased air pressure produced by an air compressor is transmitted through the air to the surface of oil in an underground reservoir. The oil, in turn, transmits the pressure to a piston, which lifts the automobile.
Cytotoxic T cells (TC cells, CTLs, T-killer cells, killer T cells) destroy virus-infected cells and tumor cells, and are also implicated in transplant rejection. These cells are defined by the expression of the CD8 protein on their cell surface. Cytotoxic T cells recognize their targets by binding to short peptides (8-11 amino acids in length) associated with MHC class I molecules, present on the surface of all nucleated cells. Cytotoxic T cells also produce the key cytokines IL-2 and IFNγ. These cytokines influence the effector functions of other cells, in particular macrophages and NK cells.
Although Mexican authorities often distinguish between homicides linked to organized crime and those that are not, the conflict has strained state resources and created an environment of impunity that has worsened crime overall. In 2009, the Mexican attorney general's office claimed that 9 of 10 victims of the Mexican drug war are members of organized crime groups, although other sources have questioned this figure. Deaths among military and police personnel are an estimated 7% of the total. The states that suffer from the conflict the most are Baja California, Guerrero, Chihuahua, Michoacán, Tamaulipas, Nuevo León, and Sinaloa.
== Clinical significance == A member of the natriuretic peptide gene family, NPPA encodes an important cardiac signaling molecule known as atrial natriuretic peptide/factor (ANP). ANP carries out endocrine functions of the heart. It acts as a diuretic by inhibiting sodium reabsorption in the kidneys. ANP also acts in the heart to prevent cardiac hypertrophy and to regulate vascular remodeling and energy metabolism. NPPA expression is varied throughout mammalian development into adulthood. Fetal expression of NPPA is associated with the formation of chamber myocardium, muscle cells of the atria and ventricles in the early developing heart. Early expression of this gene has been associated with ventricular hypertrophy in both in vitro and in vivo models. NPPA variants affect plasma ANP concentrations, blood pressure levels, and cardiovascular diseases such as atrial fibrillation (AF). ANP-deficient mice were found to have a large increase in heart and left ventricular weight in response to volume overload, which is normally prevented by proper regulation of blood pressure. Using a knock-in (KI) rat model, researchers found an AF-associated human variant in NPPA caused inflammation, fibroblast activation, atrial fibrosis, and AF in KI rats. These findings suggest NPPA is a critical gene in cardiac development and dysfunction of this gene can lead to heart problems via altered ANP levels.
Sources: en.wikipedia.org
Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.
Microbes may naturally develop resistance through genetic mutations that occur during cell division, and although random mutations are rare, many microbes reproduce frequently and rapidly, increasing the chances of members of the population acquiring a mutation that increases resistance. In contrast to that, recent research suggests that, contrary to the traditional model of rapid genetic mutation, mycobacteria maintain high genomic stability under antibiotic pressure, relying instead on phenotypic tolerance and DNA-repair mechanisms for survival. Many individuals stop taking antibiotics when they begin to feel better. When this occurs, it is possible that the microbes that are less susceptible to treatment still remain in the body. If these microbes are able to continue to reproduce, this can lead to an infection by bacteria that are less susceptible or even resistant to an antibiotic. Microbes may also get genes from each other, which makes them drug-resistant. Bacteria that have drug-resistant DNA often transfer a copy of these genes to the other bacteria. They can then multiply and thrive. This process, known as horizontal gene transfer, allows resistance genes to spread rapidly between different bacterial species through mechanisms such as conjugation, transformation, and transduction. Bacteria become resistant to antibiotics by changing themselves or acquiring resistance genes from other bacteria.
==== Other musculoskeletal disorders ==== There is limited, low-quality evidence of a slight benefit of noxious-level electrotherapy in the treatment of epicondylitis. A 2012 review found that "Small, single studies showed that some electrotherapy modalities may be beneficial" in rehabilitating ankle bone fractures, but the 2024 update of this review does not address electrotherapy. However, a 2008 review found it to be ineffective in healing long-bone fractures. A 2012 review found that evidence that electrotherapy contributes to recovery from knee conditions is of "limited quality".
The treaty did not cover sea-launched missiles, but it did include mutual on-site inspections by both nations to ensure compliance within a three-year period. By May 1991, after on-site investigations by both sides, 2,700 missiles had been destroyed. The Reagan administration also persuaded the Saudi Arabian oil companies to increase oil production. This led to a drop in the price of oil, at a time when oil was the main source of Soviet export revenues. Following the USSR's previous large military buildup, President Reagan ordered an enormous peacetime defense buildup of the United States Armed Forces; the Soviets did not respond to this by building up their military because the military expenses, in combination with collectivized agriculture in the nation, and inefficient planned manufacturing, would cause a heavy burden for the Soviet economy. It was already stagnant and in a poor state prior to the tenure of Mikhail Gorbachev who, despite significant attempts at reform, was unable to revitalise the economy. Recognizing the unsustainable burden of military spending on the Soviet GDP, the growing costs of sustaining allied and satellite regimes, systemic barriers to technological innovation, and declining domestic living standards, Gorbachev pursued a program of radical economic modernization. The implications of these combined factors were vast, leading Gorbachev to begin changing the regime's political tone.
=== Pickering emulsions and foams === Nanocelluloses can stabilize emulsions and foams by a Pickering mechanism, i.e. they adsorb at the oil-water or air-water interface and prevent their energetic unfavorable contact. Nanocelluloses form oil-in-water emulsions with a droplet size in the range of 4-10 μm that are stable for months and can resist high temperatures and changes in pH. Nanocelluloses decrease the oil-water interface tension and their surface charge induces electrostatic repulsion within emulsion droplets. Upon salt-induced charge screening the droplets aggregate but do not undergo coalescence, indicating strong steric stabilization. The emulsion droplets even remain stable in the human stomach and resist gastric lipolysis, thereby delaying lipid absorption and satiation. In contrast to emulsions, native nanocelluloses are generally not suitable for the Pickering stabilization of foams, which is attributed to their primarily hydrophilic surface properties that results in an unfavorable contact angle below 90° (they are preferably wetted by the aqueous phase). Using hydrophobic surface modifications or polymer grafting, the surface hydrophobicity and contact angle of nanocelluloses can be increased, allowing also the Pickering stabilization of foams. By further increasing the surface hydrophobicity, inverse water-in-oil emulsions can be obtained, which denotes a contact angle higher than 90°. It was further demonstrated that nanocelluloses can stabilize water-in-water emulsions in presence of two incompatible water-soluble polymers.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.